Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

I-Mab ADR (NQ: IMAB )

1.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about I-Mab ADR

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Week In Review: Zenas Raises $259 Million In IPO
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
(IMAB) - Analyzing I-MAB's Short Interest
Via Benzinga
Looking Into I-MAB's Recent Short Interest
Via Benzinga
Expert Ratings for I-MAB
Via Benzinga
Where I-MAB Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Analyst Ratings for I-MAB
Via Benzinga
5 Analysts Have This to Say About I-MAB
Via Benzinga
I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment
Via Benzinga
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories! 
Via InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
There are some solid biotech stocks on the market. But there are many more that deserve an “F” rating from the Portfolio Grader. 
Via InvestorPlace
Why Is TRACON Pharma (TCON) Stock Down 51% Today?
TRACON Pharmaceuticals (TCON) stock is falling on Tuesday morning following an update on a legal battle with I-Mab (IMAB). 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we check out the latest news worth watching on Tuesday! 
Via InvestorPlace
Last Day Of Q1
Wall Street bonuses fell 26% last year. This was the biggest drop since 2008. Wall Street is estimated to be responsible for 16% of all economic activity in NYC. Wild nights out for ibankers slowing... 
Via Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.